PharmaCyte Biotech Market Risk Adjusted Performance
| PMCB Stock | | | USD 0.69 -0.01 -1.43% |
The Market Risk Adjusted Performance indicator for PharmaCyte Biotech is constructed from normalized market data. Values reflect historical observations within the available dataset. PharmaCyte Biotech has a market cap of 7.37 M, ROE of -8.24%. Allocation context is available in
Your Equity Center. Portfolio composition is shown for contextual purposes. The summary draws on available position and value data. The information is presented without directional commentary. The allocation includes a position in PharmaCyte Biotech. The position falls within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in discontinued.
For more information on how to buy PharmaCyte Stock please use our
How to Buy PharmaCyte Stock guide.
PharmaCyte Biotech has current Market Risk Adjusted Performance of 0.2441.
MRAP | = | ER[a] + (1/BETA - 1) | X | ER[a] - RFR) |
| = | 0.2441 | |
| ER[a] | = | Expected return on investing in PharmaCyte Biotech |
| RFR | = | Risk Free Rate of return. Typically T-Bill Rate |
| BETA | = | Beta of the asset with market or selected benchmark. |
Market Risk Adjusted Performance Peers Comparison
Market Risk Adjusted Performance Relative To Other Indicators
PharmaCyte Biotech is rated
below average in market risk adjusted performance among leading competitors. It is currently under evaluation in maximum drawdown among leading competitors reporting about
90.34 of Maximum Drawdown per Market Risk Adjusted Performance. At
90.34 , PharmaCyte Biotech's Maximum Drawdown-to-Market Risk Adjusted Performance multiple reflects the spread between these metrics
Other Technical Indicators